uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...
Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
Food Allergy Research & Education11h
Food Allergy Nonprofit, FARE Announces ATANIS Biotech AG as the Winner of Phase 2 of its Innovation Award Diagnostic Challenge
The FARE Innovation Award Diagnostic Challenge is made possible through generous support from the Naddisy Foundation, the ...
Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...
Daily13h
Dr Reddy's Laboratories Gets CDSCO Panel Nod To Study Semaglutide in Type 2 Diabetes Mellitus
Semaglutide is a GLP-1 agonist that works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a glucagon-like ...
manilatimes19h
Zealand Pharma Announces Financial Results for the Full Year 2024
Zealand Pharma achieved notable organizational growth in 2024 with a 30% increase in the number of employees compared to 2023 ...